Strategic portfolio management, tight integration of the sales force with the rest of the business and the proper use of sales and marketing analytics will be critical to meeting the demands in line with the changing China marketplace.

Companies with a narrow portfolio companies and with a very few blockbuster products can be in danger when they are confronted in a healthcare system with strict reimbursement guidelines. Companies with slightly broader portfolios, are less vulnerable with less risks of reimbursement issues.

Generic companies having very broad have the situation that each single product is less crucial to the success of the company. However, generic companies can be at risk in price wars or when a new innovative molecule is launched that replaces a generic brand.

Our analysis can optimize sales and minimize risk by moving to a portfolio strategy that relies more heavily on a broad mixture of drugs in various revenue classifications. We agree that strategic portfolio management is critical to success in China. Also we stress the importance of developing a broad-based portfolio. We believe that when it comes to your portfolio, you have to have several legs to stand on.